Comparison of 2‐year outcomes between zotarolimus‐eluting and everolimus‐eluting new‐generation cobalt–chromium alloy stents in real‐world diabetic patients

Publisher： John Wiley & Sons Inc

E-ISSN： 1522-726x|86|1|E11-E18

ISSN： 1522-1946

Source： CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS, Vol.86, Iss.1, 2015-07, pp. : E11-E18

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Clinical outcomes of real‐world patients treated with an amphilimus polymer‐free stent versus new generation everolimus‐eluting stents

CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS, Vol. 86, Iss. 7, 2015-12 ,pp. : 1168-1176

John Wiley & Sons Inc

Access to resources Recommend Favorite

Comparison of 5‐year outcomes of paclitaxel‐eluting and endeavor zotarolimus‐eluting stents in New York

CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS, Vol. 91, Iss. 1, 2018-01 ,pp. : 9-16

John Wiley & Sons Inc

Access to resources Recommend Favorite

Comparison of 2‐year clinical outcomes between zotarolimus‐, sirolimus‐, and paclitaxel‐eluting stents in real life clinical practice

CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS, Vol. 83, Iss. 3, 2014-02 ,pp. : 349-359

John Wiley & Sons Inc

Access to resources Recommend Favorite

Risk and timing of clinical events according to diabetic status of patients treated with everolimus‐eluting bioresorbable vascular scaffolds versus everolimus‐eluting stent: 2‐year results from a propensity score matched comparison of ABSORB EXTEND and SPIRIT trials

CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS, Vol. 91, Iss. 3, 2018-02 ,pp. : 387-395

John Wiley & Sons Inc

Access to resources Recommend Favorite

Four‐year comparative effectiveness of bare‐metal and everolimus‐eluting stents in New York

CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS, Vol. 91, Iss. 3, 2018-02 ,pp. : 417-424

John Wiley & Sons Inc

Access to resources Recommend Favorite